Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUEST quetiapine effectiveness study in borderline personality disorder
ISRCTN16864220Phase 3Recruiting
- Sponsor
- University of Liverpool
- Start
- Feb 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in borderline personality disorder (BPD) comparing Quetiapine with Placebo (2 arms). Primary endpoint: Symptoms of borderline personality disorder. Started Feb 2026; status: recruiting.
02
Drugs
quetiapine
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on ISRCTN16864220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16864220.